伊匹木单抗联合紫杉醇与卡铂治疗晚期鳞状非小细胞肺癌的III期试验
这项随机双盲III期研究在晚期鳞状非小细胞肺癌患者中比较一线紫杉醇+卡铂联合伊匹木单抗或安慰剂的疗效与安全性。956例随机分组,749例接受至少一剂盲法治疗;伊匹木单抗组中位OS 13.4个月 vs 安慰剂组12.4个月(HR 0.91,95%CI 0.77-1.07,P=0.25),未延长OS。
要点
- 化疗联合伊匹木单抗较化疗联合安慰剂未延长晚期鳞状NSCLC的OS。
- 中位OS:伊匹木单抗组13.4个月 vs 安慰剂组12.4个月,HR 0.91(95%CI 0.77-1.07,P=0.25)。
- 3/4级治疗相关不良事件:伊匹木单抗组51% vs 安慰剂组35%,治疗相关死亡7例 vs 1例。
核心结论
- 在晚期鳞状NSCLC患者中,一线化疗联合伊匹木单抗较单纯化疗未延长总生存。
研究设计与样本
- 随机、双盲、III期研究,纳入IV期或复发、未接受化疗的鳞状NSCLC患者。
- 患者按1:1随机接受紫杉醇+卡铂联合盲法伊匹木单抗10 mg/kg或安慰剂,每3周一次,采用分阶段诱导方案:共6个化疗周期,伊匹木单抗或安慰剂从第3至第6周期给予,诱导治疗后对疾病稳定或更好者每12周给予伊匹木单抗或安慰剂维持治疗。
- 主要终点为接受至少一剂盲法研究治疗患者的总生存。
- 956例随机分组,749例接受至少一剂盲法研究治疗(化疗联合伊匹木单抗组n=388;化疗联合安慰剂组n=361)。
主要发现
- 中位OS:化疗联合伊匹木单抗组13.4个月 vs 化疗联合安慰剂组12.4个月(HR 0.91;95%CI 0.77至1.07;P=0.25)。
- 中位无进展生存:两组均为5.6个月(HR 0.87;95%CI 0.75至1.01)。
- 3或4级治疗相关不良事件发生率:化疗联合伊匹木单抗组51% vs 化疗联合安慰剂组35%。
- 任何级别严重治疗相关不良事件发生率:化疗联合伊匹木单抗组33% vs 化疗联合安慰剂组10%。
- 导致停药的治疗相关不良事件发生率:化疗联合伊匹木单抗组28% vs 化疗联合安慰剂组7%。
临床怎么用
- 作者结论认为,在晚期鳞状NSCLC患者中,一线化疗联合伊匹木单抗较单纯化疗未延长总生存;原文未据此给出推荐。
- 作者指出,化疗联合伊匹木单抗的安全性特征与既往肺癌和黑色素瘤研究中所观察到的结果一致。
- 作者提及,正在进行的 study 正在该人群中评价伊匹木单抗联合纳武利尤单抗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Patients with squamous non-small-cell lung cancer (NSCLC) have poor prognosis and limited treatment options. This randomized, double-blind, phase III study investigated the efficacy and safety of first-line ipilimumab or placebo plus paclitaxel and carboplatin in advanced squamous NSCLC. Patients and Methods Patients with stage IV or recurrent chemotherapy-naïve squamous NSCLC were randomly assigned (1:1) to receive paclitaxel and carboplatin plus blinded ipilimumab 10 mg/kg or placebo every 3 weeks on a phased induction schedule comprising six chemotherapy cycles, with ipilimumab or placebo from cycles 3 to 6 and then, after induction treatment, ipilimumab or placebo maintenance every 12 weeks for patients with stable disease or better. The primary end point was overall survival (OS) in patients receiving at least one dose of blinded study therapy. Results Of 956 randomly assigned patients, 749 received at least one dose of blinded study therapy (chemotherapy plus ipilimumab, n = 388; chemotherapy plus placebo, n = 361). Median OS was 13.4 months for chemotherapy plus ipilimumab and 12.4 months for chemotherapy plus placebo (hazard ratio, 0.91; 95% CI, 0.77 to 1.07; P = .25). Median progression-free survival was 5.6 months for both groups (hazard ratio, 0.87; 95% CI, 0.75 to 1.01). Rates of grade 3 or 4 treatment-related adverse events (TRAEs), any-grade serious TRAEs, and TRAEs leading to discontinuation were numerically higher with chemotherapy plus ipilimumab (51%, 33%, and 28%, respectively) than with chemotherapy plus placebo (35%, 10%, and 7%, respectively). Seven treatment-related deaths occurred with chemotherapy plus ipilimumab, and one occurred with chemotherapy plus placebo. Conclusion The addition of ipilimumab to first-line chemotherapy did not prolong OS compared with chemotherapy alone in patients with advanced squamous NSCLC. The safety profile of chemotherapy plus ipilimumab was consistent with that observed in previous lung and melanoma studies. Ongoing studies are evaluating ipilimumab in combination with nivolumab in this population.
引用
- Govindan R, Szczesna A, Ahn MJ, et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017. PMID: 28854067. doi:10.1200/JCO.2016.71.7629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。